Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps (Exact Sciences)

At ACG 2025, Exact Sciences presented compelling new research showing how its Cologuard® and Cologuard Plus™ tests drive higher colorectal cancer screening completion rates — especially among underserved and older populations. Studies revealed that mt-sDNA users were 74% more likely to complete screening than FIT users, and that digital outreach doubled engagement. Modeling also showed next-gen Cologuard detecting 5.5x more precancers and cutting treatment costs versus FIT. Together, the findings strengthen the case for noninvasive, at-home testing as a cornerstone of equitable CRC prevention.